Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial
Authors
Nasser Ebrahimi Daryani1,*, Babak Haghpanah2, Ali Reza Sayyah2, Ali Asad Hashtroudi2, Mohammad Bashashati2, Parisa Poursamimi2, Mehri Nikbin2
1Tehran University of Medical Sciences, Imam Khomeini Hospital & Study Group of Interferon in Iran (SG.IFN.IR), nebrahim@sina.tums.ac.ir, Tehran, IR.Iran
2Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, IR.Iran
*Corresponding Author: Tehran University of Medical Sciences, Imam Khomeini Hospital & Study Group of Interferon in Iran (SG.IFN.IR), nebrahim@sina.tums.ac.ir, Tehran, IR.Iran. Tel: 0098 21 8799446. Fax: 0098 21 8799840. Email: nebrahim@sina.tums.ac.ir
How to Cite:Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
Abstract
Background and aims: Peginterferon alpha-2a is a known standard therapy for patients with chronic HCV infection. However efficacy and safety of this treatment is still unclear in regional settings. This study was designed to clarify efficacy and safety of peg-interferon based therapy in Iranian patients.
Methods: 23 patients were treated with Peginterferon alpha-2a in combination with ribavirin for 48 weeks. The patients were observed for adverse effects and response to therapy during treatment and 24 weeks after the end of therapy.
Results: Early virologic response, end of treatment response, and sustained virologic response rates were 86.9 % (20/23), 82.6 % (19/23), and 78.3 % (18/23) respectively. The most common adverse effects in descending order were flue-like symptoms (74%), mood changes (48%), and weight loss (43%).
Conclusion: Combination therapy with Peginterferon alpha-2a and ribavirin for 48 weeks is an effective treatment with minimal adverse effects.
Highlights
Copyright
© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Sep
2004
Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian
Seyed Moayed Alavian,
Behzad Hajarizadeh,
Bashir Hajibeigi,
Taher Doroudi,
Amir Kambiz Hamadanizadeh,
Koroush Abar
Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:
30
Sep
2004
Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C
Mohammad Reza Zali,
Hamid Mohaghegh Shalmani,
Mohsen Norouzinia,
Amir Hooshang MohammadAlizadeh,
Azita Nowroozi,
Negar Behrouz
Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
1
Jan
2006
Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study
SM Alavian,
A Kabir,
B Hajarizadeh,
M Nayebpour,
T Dorodi,
FE Baralle
Alavian S, Kabir A, Hajarizadeh B, Nayebpour M, Dorodi T, et al. Preliminary Report of Interferon ?2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study. Shiraz E-Med J. 2006;7(1):20390. doi:
1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari
Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955
29
Sep
2015
Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
Mahdiyar Pouresmaeeli,
Seyed Moayed Alavian,
Maryam Keshvari,
Shima Salimi,
Leila Mehrnoush
Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon. 2015;15(9):e30780. doi: https://doi.org/10.5812/hepatmon.30780
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 0
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 4 hours ago
- OpenAlex: 0
Last Update: 6 hours ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0